Literature DB >> 20884239

Pathologic assessment of radiofrequency ablation of pulmonary metastases.

Jeffrey D Jaskolka1, John R Kachura, David M Hwang, Ming S Tsao, Thomas K Waddell, Murray R Asch, Gail E Darling, Michael R Johnston.   

Abstract

PURPOSE: To evaluate pathologically the effectiveness of radiofrequency (RF) ablation in the treatment of pulmonary metastases.
MATERIALS AND METHODS: Patients with multiple pulmonary metastases scheduled for surgical resection were prospectively enrolled. Patients underwent RF ablation of one percutaneously accessible tumor and within 2-4 weeks underwent surgical resection of the ablated tumor and any additional lesions. Resected tumors all were assessed by routine light microscopy, and selected tumors were assessed by immunohistochemistry with MIB1 and proliferative cell nuclear antigen (PCNA). Relationship of ablation zone to the tumor and viability of the ablated tumors were assessed.
RESULTS: Nine patients (four men and five women) 46-76 years of age were included in the study. Four patients had metastatic colorectal carcinoma, and five patients had metastases from soft tissue sarcomas. Ablated tumors ranged from 1.0-3.0 cm in diameter. Each target lesion was completely encompassed by the ablation zone. All tumor tissue within the ablation zone showed characteristic changes of coagulative necrosis with hematoxylin and eosin staining. Tumors showed preservation of MIB1 staining but loss of PCNA protein staining. RF ablation resulted in complete coagulative necrosis of all the pulmonary metastases treated in the study.
CONCLUSIONS: Although this series is small, it provides histologic support for RF ablation as an effective treatment for selected pulmonary metastases.
Copyright © 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884239     DOI: 10.1016/j.jvir.2010.06.023

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  9 in total

Review 1.  [Local treatment of solitary intrapulmonary, malignant nodules].

Authors:  J Op den Winkel; F Eichhorn; S Rieken; H Dienemann
Journal:  Radiologe       Date:  2017-02       Impact factor: 0.635

2.  Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.

Authors:  Zhigang Wei; Xin Ye; Xia Yang; Guanghui Huang; Wenhong Li; Jiao Wang; Xiaoying Han
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

Review 3.  Image-Guided Thermal Ablative Therapies in the Treatment of Sarcoma.

Authors:  Scott M Thompson; John J Schmitz; Grant D Schmit; Matthew R Callstrom; Anil Nicholas Kurup
Journal:  Curr Treat Options Oncol       Date:  2017-04

4.  Long-term survival following radiofrequency ablation of lung metastases in an elderly patient with calcaneal osteosarcoma: A case report and review of the literature.

Authors:  Hiroyuki Futani; Haruyuki Takaki; Tatsuo Sawai; Junichi Taniguchi; Yasukazu Kako; Yoshi-Hiro Ide; Koichiro Yamakado; Toshiya Tachibana
Journal:  Medicine (Baltimore)       Date:  2021-08-27       Impact factor: 1.889

Review 5.  Lung cancer ablation: what is the evidence?

Authors:  Thierry de Baere; Geoffroy Farouil; Frederic Deschamps
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

6.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases.

Authors:  T de Baère; A Aupérin; F Deschamps; P Chevallier; Y Gaubert; V Boige; M Fonck; B Escudier; J Palussiére
Journal:  Ann Oncol       Date:  2015-02-16       Impact factor: 32.976

7.  Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know.

Authors:  Shivank Bhatia; Keith Pereira; Prasoon Mohan; Govindarajan Narayanan; Medhi Wangpaichitr; Niramol Savaraj
Journal:  Indian J Radiol Imaging       Date:  2016 Jan-Mar

Review 8.  Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy.

Authors:  Mario Ghosn; Stephen B Solomon
Journal:  Cancers (Basel)       Date:  2021-10-16       Impact factor: 6.639

9.  Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.

Authors:  Constantinos T Sofocleous; Sandeep K Garg; Perry Cohen; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Robert J Downey; William D Travis; Stephen B Solomon
Journal:  Ann Surg Oncol       Date:  2013-07-30       Impact factor: 4.339

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.